Loading
VC004 is an experimental small-molecule drug from Jiangsu vcare pharmaceutical technology co. in phase 3 trials, with its target not yet stated publicly.
VC004 is a small-molecule drug developed by Jiangsu vcare pharmaceutical technology co.. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06658353 (Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumours). The largest, NCT06658353, plans to enrol 54 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.VC004 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"VC004" OR ABSTRACT:"VC004") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VC004, not a curated reading list.